Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRE | P78334 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950739 | 1.00 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25863829 | 0.83 | SMN1; SMN2 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28322999 | 0.81 | NNMT (0.46) | ALDH1A1SMN1; SMN2KDM4ETDP1MAPT | |
| SCHEMBL30200373 | 0.80 | HCAR2 (0.47) | GABRG2GABRB3GABRA5GABRA3KDM5B | |
| SCHEMBL21964163 | 0.78 | GAA (0.40) | KDM5BALDH1A1SMN1; SMN2RXFP1KDM4E | |
| SCHEMBL161825 | 0.76 | KDM5B (0.46) | KDM5BALDH1A1SMN1; SMN2KDM4CKDM4E | |
| SCHEMBL4769775 | 0.76 | KDM5B (0.46) | KDM5BALDH1A1SMN1; SMN2KDM4CKDM4E | |
| SCHEMBL5769273 | 0.76 | KDM4E (0.52) | KDM5BALDH1A1SMN1; SMN2KDM4CKDM4E | |
| SCHEMBL1623759 | 0.74 | SMN1; SMN2 (0.53) | KDM5BALDH1A1SMN1; SMN2KDM4CKDM4E | |
| SCHEMBL20928648 | 0.74 | KDM5B (0.45) | KDM5BALDH1A1SMN1; SMN2KDM4CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| CN-101679304-A | Pyridazine-, pyridine- and pyrane-derivatives as GPBAR1 agonisis | NOVARTIS AG | 2010-03-24 | — | — | CN | claimed |
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | ARISTA LUCA | 2010-02-25 | — | — | US | claimed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | claimed |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-115052860-B | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4311577-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Ji Xing Pharmaceuticals Hong Kong Limited (HK) | 2024-01-31 | — | — | EP | disclosed |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2008125627-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISIS | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1869017-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2005112925-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | GABRP 1695/4885GABRD 1047/4885GABRA1 593/4885 |
| US-20230382911-A1 | PYRAZOLEAMIDE DERIVATIVES | P2RY1, P2RX1, P2RX5 | GABRP 1032/4885GABRD 2232/4885GABRA1 1074/4885 |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | GABRP 3680/4885GABRD 2638/4885GABRA1 2982/4885 |
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | GABRP 1695/4885GABRD 1047/4885GABRA1 593/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | GABRP 1154/4885GABRD 2083/4885GABRA1 2216/4885 |
| US-20070275960-A1 | Phenyl and pyridyl compounds for inflammation and immune-related uses | NLRP3, CCR1, NLRP1 | GABRP 2437/4885GABRD 4645/4885GABRA1 2602/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | GABRP 3553/4885GABRD 4779/4885GABRA1 4271/4885 |
| US-20100048579-A1 | PYRIDAZINE-, PYRIDINE- AND PYRANE-DERIVATIVES AS GPBAR1 AGONISTS | GPBAR1, GPER1, ADRB1 | GABRP 256/4885GABRD 378/4885GABRA1 91/4885 |
| US-20240336574-A1 | METHYL-SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | P2RX5, HRH4, TRPV1 | GABRP 1839/4885GABRD 2737/4885GABRA1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.